Navigation Links
Children's Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics

BOSTON, Nov. 9, 2011 /PRNewswire-USNewswire/ -- Children's Hospital Boston and Pfizer Inc. (NYSE: PFE) have launched a new collaborative program aimed at identifying potential drug therapies for Duchenne muscular dystrophy (DMD). At the heart of the one-year collaborative research agreement is a novel exchange of expertise that brings the respective strengths of academia and industry together in a framework that could hold promise for benefitting DMD patients in the future.

The agreement focuses on the work of the laboratory of Louis Kunkel, Ph.D., Director of the Program in Genomics at Children's Hospital Boston and discoverer of the dystrophin gene that underlies the biology of DMD. In March 2011, Kunkel and colleagues announced the results of their efforts to screen 1,200 chemicals already approved for human use in a zebrafish model of DMD for any that might have a restorative effect on muscle tissue. Kunkel's team – one of several at Children's engaged in research on rare or orphan diseases – found that several had the desired effect in the zebrafish model, including compounds owned by Pfizer.

Through the agreement, Pfizer will, via its Orphan and Genetic Diseases Research Unit, provide Kunkel access to select proprietary compounds, as well as relevant data about these compounds. Pfizer is also committing internal resources to the project such as medicinal chemistry.

In collaboration with Pfizer's Carl Morris, Ph.D., Kunkel's laboratory will test the compounds provided by Pfizer in the DMD zebrafish model, with an eye toward identifying candidates for further preclinical development.

"This agreement brings together the best of two worlds, namely Pfizer's ability to develop promising new compounds and our ability to test them in physiologically relevant models," Kunkel said. "To have Pfizer show this level of interest in DMD is very exciting, and I am pleased to have this opportunity for us to put our complementary resources to work together.

"Here at Children's, we have the expertise in basic science and clinical care," Kunkel continued, "but not the crucial chemical and development background that Pfizer has brought to the table."

"We see this as a truly novel collaboration that combines the efforts of a world-class academic DMD research laboratory with our chemical and preclinical expertise," said Ed Mascioli, M.D., Vice President and Chief Scientific Office of Pfizer's Orphan and Genetic Diseases Research Unit. "We are proud to be working with someone of Dr. Kunkel's stature in the DMD research arena."

"This agreement helps line up the pieces of the drug development pipeline for the benefit of children and adults with DMD," said Erik Halvorsen, director of technology and business development for Children's. "It is rare to see an industrial partner allow this kind of access, and we are very pleased to have established this novel arrangement with Pfizer."

This is not the only research agreement to be signed by Pfizer and Children's in 2011. In June, Pfizer announced that Children's would be one of seven Boston-area hospitals to join its Centers for Therapeutic Innovation, which aim to facilitate and support joint drug discovery and development, from the conception of an idea through early clinical trials. The DMD research agreement stands as a separate arrangement between Pfizer and Children's.

Children's Hospital Boston is home to the world's largest research enterprise based at a pediatric medical center, where its discoveries have benefited both children and adults since 1869. More than 1,100 scientists, including nine members of the National Academy of Sciences, 11 members of the Institute of Medicine and nine members of the Howard Hughes Medical Institute comprise Children's research community. Founded as a 20-bed hospital for children, Children's Hospital Boston today is a 395 bed comprehensive center for pediatric and adolescent health care grounded in the values of excellence in patient care and sensitivity to the complex needs and diversity of children and families. Children's also is the primary pediatric teaching affiliate of Harvard Medical School. For more information about research and clinical innovation at Children's, visit:

 Keri Stedman

Lauren StarrChildren's Hospital Boston 

Pfizer Inc.617-919-3110

SOURCE Children's Hospital Boston
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Childrens Hospital of Philadelphia Receives Grand Challenges Explorations Funding
2. Childrens Hospitals and Clinics of Minnesota Opens New Helipad on its Minneapolis Campus
3. UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana
4. St. John Hospital 1st in Region to Offer Innovative Chemotherapy Delivery System
5. CareFusion Announces New Ventilation Solution to Help Hospitals Provide Improved Patient Care and Reduce Costs
6. DMC Childrens Hospital of Michigan Selects Allscripts Electronic Health Record for Employed and Affiliated Physicians
7. Novation Commends the White House for Its Support and Advancement of Solutions for American Hospitals Drug Shortage Crisis
8. A Heart for Jordan Merecka: Texas Childrens Hospitals First Total Artificial Heart Patient Receives the Gift of a Donor Heart
9. Mevion Medical Systems Delivers the Worlds First Superconducting Synchrocyclotron for Proton Therapy to Barnes Jewish Hospital
10. Australias Prince of Wales Hospital Launches New Era of Targeted Lung Cancer Treatments with Elektas Advanced 4D Motion Management Technology
11. DMC Harper University Hospital is the First in Michigan to Utilize New Device for Brain Tumor Removal
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 On Tuesday, November ... bellwether trial against Wright Medical Technology, Inc. for ... Conserve metal-on-metal hip implant device, awarded $11 million ... two week trial and three days of deliberations, ... device was defectively designed and unreasonably dangerous, and ...
(Date:11/25/2015)... Allergan plc (NYSE: AGN ) today announced that it ... State Attorney General,s Office to end the litigation ... with the Attorney General over the decision of Forest Laboratories, ... the now generic version of memantine immediate release tablets.  Under ... its counterclaims against New York , and ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... Indosoft Inc., developer and distributor of the ... to improve system efficiency and reliability. , The new Q-Suite 6 platform is based ... system avoids locking itself into a specific piece of software for many key components ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of the ... stellar workplace culture with the company’s Cincinnati office being named a finalist among ... was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati Best ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is donating ... Beat ” campaign. The partnership between the two groups began in 2014 with Vitalalert ... cause. , MAP International was founded in 1954 and is an international Christian-based health ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health ... launches new Wimbledon Athletics Facebook page to educate the public, parents ... cardiac abnormalities. About 2,000 people under the age of 25 die from sudden ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a ... tracking systems. The new app features a more intuitive SleepScore™ that rates sleep quality ... you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the data ...
Breaking Medicine News(10 mins):